Watchmaker Genomics Unveils New Sequencing Technologies to Improve NGS Workflow Efficiency and Data Accuracy at ESHG 2026
Watchmaker Genomics, a company recognized for its high-performance next-generation sequencing (NGS) workflow solutions, has announced the launch of two innovative technologies aimed at addressing some of the most persistent challenges faced by genomic researchers and sequencing laboratories. The company will officially introduce the new products at the European Society of Human Genetics (ESHG) 2026 conference, highlighting its continued commitment to improving sequencing scalability, workflow efficiency, and data quality.
The new offerings include the EquiPlex™ Normalization Kit and the Equinox® Prime Library Amplification Master Mix. Together, these technologies are designed to streamline critical steps in sequencing workflows while enhancing the accuracy and reliability of genomic data. By tackling common bottlenecks associated with library normalization and amplification, Watchmaker Genomics aims to help researchers generate higher-quality sequencing results while reducing operational complexity.
Addressing Long-Standing Challenges in Sequencing Workflows
As genomic research expands across clinical diagnostics, drug discovery, population genomics, and precision medicine, sequencing laboratories are processing increasingly large numbers of samples. While sequencing instruments have become faster and more powerful, several key workflow challenges remain unresolved, particularly in sample preparation and library processing.
Library normalization and amplification continue to be areas where inefficiencies can impact productivity, increase costs, and compromise data quality. Inconsistent library pooling can lead to uneven sequencing coverage, while amplification artifacts can introduce errors that affect downstream analyses, especially when detecting complex genetic variants.
Watchmaker Genomics developed its latest technologies to address these issues directly. Leveraging the company’s expertise in protein engineering and integrated workflow development, the new products are intended to simplify laboratory operations while supporting high-quality sequencing outcomes.
According to Trey Foskett, Chief Executive Officer of Watchmaker Genomics, researchers continue to encounter many of the same operational bottlenecks despite advances in sequencing technology.
He explained that while sequencing workflows have grown significantly in scale and complexity, fundamental challenges remain. The newly introduced technologies were designed not only to enhance sequencing data quality but also to simplify workflows and enable laboratories to operate more efficiently as throughput demands increase.
EquiPlex™ Normalization Kit Introduces a New Approach to Library Pooling
One of the centerpiece launches at ESHG 2026 is the EquiPlex™ Normalization Kit, which introduces a novel method for library normalization based on CRISPR-Cas9 technology.
Traditionally, library normalization requires multiple steps, including concentration measurement, quality control assessments, dilution calculations, and careful pipetting of varying sample volumes. These processes can be labor-intensive, difficult to automate, and prone to human error, particularly when laboratories handle large numbers of samples.
The EquiPlex solution reimagines this process by using CRISPR-Cas9 as a stoichiometric molecular binding tool rather than as a genome-editing enzyme. Instead of cutting DNA, the system captures a fixed number of molecules from each sequencing library regardless of the library’s starting concentration.
This unique approach enables rapid and highly consistent normalization across multiple samples, reducing variability during library pooling. Because the technology equalizes libraries automatically, laboratories can eliminate several traditional workflow steps, including concentration-based quality control checks and manual dilution calculations.
The result is a streamlined normalization process that supports greater automation and improved consistency across sequencing projects.
Importantly, EquiPlex has been designed to integrate seamlessly into existing sequencing workflows. It is compatible with RNA sequencing, DNA sequencing, and methylation sequencing applications, allowing laboratories to adopt the technology without redesigning established library preparation procedures.
Researchers working in high-throughput environments may particularly benefit from the simplified workflow and increased pooling consistency. Uneven pooling can often result in under-sequenced samples that require additional sequencing runs to achieve target coverage levels, increasing both time and costs.
Graham Wiley, PhD, Director of the Clinical Genomics Center at the Oklahoma Medical Research Foundation, noted that library normalization has long been a source of frustration for many laboratories. He explained that previous workflows often produced enough variability to require additional sequencing in order to reach desired coverage targets. According to Wiley, EquiPlex has provided the level of pooling consistency that his team had been seeking.
Expanding CRISPR-Based Workflow Innovation
Beyond its immediate application in library normalization, Watchmaker Genomics is also adapting the EquiPlex technology as part of a broader sequencing workflow strategy.
The company is incorporating the CRISPR-enabled normalization approach into the development of a future PCR-free whole genome sequencing (WGS) solution. This next-generation workflow is expected to streamline multiple steps involved in genome sequencing, including DNA fragmentation, normalization, and library construction.
PCR-free workflows are increasingly attractive because they can reduce amplification biases and improve the representation of genomic regions that are difficult to sequence. By integrating normalization directly into the workflow, Watchmaker hopes to deliver highly reproducible and scalable genome sequencing solutions for research and clinical laboratories.
Equinox® Prime Enhances Amplification Accuracy
The second major product debuting at ESHG 2026 is the Equinox® Prime Library Amplification Master Mix, a new amplification solution engineered to improve sequencing accuracy while maintaining strong overall performance.
Library amplification plays a critical role in many sequencing workflows, but it can also introduce errors that affect variant detection. One common issue is polymerase slippage, which occurs when DNA polymerases misread repetitive sequences or homopolymer regions, leading to insertion and deletion (indel) artifacts.
These errors can be particularly problematic in applications where accurate indel detection is essential, including cancer genomics and microsatellite instability (MSI) analysis.
Equinox Prime was specifically developed to reduce polymerase slippage and improve accuracy in challenging genomic regions. By minimizing amplification-induced errors, the technology supports more reliable variant calling and improved confidence in sequencing results.
The benefits extend beyond indel accuracy. According to Watchmaker, Equinox Prime also delivers low overall error rates, high library yields, and uniform coverage across genomic regions with varying GC content.
These characteristics make the amplification solution suitable for a wide range of sequencing applications, including whole genome sequencing, whole exome sequencing, and other research workflows where amplification quality directly influences downstream data performance.
Brian Kudlow, Chief Scientific Officer of Watchmaker Genomics, emphasized that researchers have traditionally been forced to make compromises when selecting amplification technologies. Laboratories often need to balance sequencing accuracy against factors such as yield and coverage uniformity.
He explained that Equinox Prime was engineered to eliminate these trade-offs by providing enhanced indel accuracy in repetitive regions while simultaneously delivering low error rates, robust yields, and even GC coverage.
Showcasing Innovation at ESHG 2026
Watchmaker Genomics will formally introduce both technologies during ESHG 2026 in Gothenburg, Sweden. The company plans to feature the products in a workshop titled “From Multiomics to Multiplexing: Integrated Advances in DNA, RNA, and Epigenomic Profiling,” scheduled for June 15.
The session will explore emerging strategies for improving sequencing workflows across multiple genomic applications. Topics will include methods for enhancing sequencing quality, simplifying laboratory processes, and enabling scalable genomics research across DNA, RNA, and epigenetic studies.
The debut of EquiPlex and Equinox Prime represents another step in Watchmaker Genomics’ effort to provide researchers with integrated solutions that address practical challenges in modern sequencing laboratories. As genomic studies continue to expand in scale and complexity, innovations that improve workflow efficiency while maintaining data quality are expected to play an increasingly important role in advancing research and clinical genomics worldwide.
About Watchmaker Genomics
Watchmaker Genomics is a life sciences company focused on developing high-performance tools that empower genomic research and clinical applications. Leveraging expertise in protein engineering and next-generation sequencing, Watchmaker delivers precision reagents and platforms that enable superior accuracy, efficiency, and cost-effectiveness in molecular analysis. The company is dedicated to advancing breakthrough technologies to support innovations in cancer detection, epigenetics, and liquid biopsy applications.
